Rosetta Omics

23/08/2026

Rosetta Omics Founder & CEO interview at Station F

Rosetta Omics Founder & CEO interview with the Universités Pharmace...

05/08/2024

Breaking news!

In a world where leaders struggle to preserve peace and protect the lives of their people, and where diseases like cancer and conflicts claim lives daily, we remain committed to making a difference by working very hard to save lives.

I am happy to share with Rosetta Omics ' current and future partners that we have successfully completed our first proof of concept (POC) study in colon cancer.

Our team continues to analyze additional biopsies, enhancing our AI algorithm with more data.

Moreover, we will be intiating soon, two more proof of concept (POC) studies in liver and kidney cancers, working with leading oncology KOLs in top European hositals.

Stay tuned for more updates!

08/04/2024

🚀 Breaking News ! 🚀

We are thrilled to announce that Rosetta Omics has been accepted into the prestigious Agoranov incubator in Paris! 🎉
This is a significant milestone for Rosetta, and we couldn't be more excited about the opportunities that lie ahead.

Agoranov is renowned for nurturing and propelling innovative companies like ours, and we are honored to be a part of their vibrant ecosystem. It has already incubated more than 450 startups, including 5 "unicorns" (valued at over one billion dollars). Incubated startups have already managed to create more than 12,500 jobs and have raised over 2.5 billion euros from private funds".

At Rosetta Omics, we are dedicated to revolutionizing the field of oncology precision medicine and with Agoranov's invaluable resources, mentorship, and network, we are confident that we will accelerate our growth and make a lasting impact in the healthcare industry.

As we embark on this new chapter of our journey, we are deeply grateful for the support and encouragement from our team, advisors, and partners who have been instrumental in getting us to this point.

Stay tuned for more updates as we embark on this exciting journey with Agoranov! 💼✨

02/03/2024

🚀 Big News Update from Rosetta Omics! 🎉

We're thrilled to share that our collaborative efforts have paid off as we join forces with esteemed partners in a groundbreaking €1.5 million project focused on early detection and diagnosis of osteoarthritis! 💡

Although Rosetta Omics is primarily known for our precision oncology initiatives, we're excited to broaden our horizons and contribute to this vital research endeavor. Our partnership with Maastricht University, along with a stellar consortium including INIBIC Osteoarthritis Foundation, RIVM National Institute for Public Health and the Environment, and others, underscores our commitment to driving innovation beyond traditional boundaries.

The KIC call, 'Early detection of osteoarthritis – Innovations for detection and diagnosis,' backed by NWO and the Dutch Arthritis Society, aims to revolutionize osteoarthritis management.

By developing cutting-edge diagnostic tools and predictive biomarkers, we're paving the way for early intervention and personalized treatment pathways.

With 1.5 million people currently affected by osteoarthritis in the Netherlands alone, the urgency of our mission cannot be overstated. Through interdisciplinary collaboration and innovative technologies like artificial intelligence and digital PCR, we're poised to make a tangible impact on healthcare outcomes and quality of life for millions worldwide.

This project, aptly named CircBioCare:
Circulating epigenetic and protein biomarkers for early OA diagnosis in primary care and patient stratification, marks just the beginning of Rosetta Omics' journey in European collaborative projects. We're honored to be at the forefront of this critical research initiative, driven by our shared vision of 'Living longer in good health.'

Thank you to all our partners, collaborators, and supporters who make endeavors like these possible. Together, we're shaping the future of healthcare one breakthrough at a time! 🌟

Thank you Berta Cillero Pastor for leading this effort and the project and looking forward to working with you and all other partners.

31/01/2024

Rosetta Omics team: Our CEO Dr. Wahid Awad, Ph.D. MBA and our CSO Dr. Kevin Adam, PhD, MBE today at the first Artificial Intelligence & Cancers Association Day (Filière Intelligence Artificielle & Cancers ) at PariSanté Campus ).

A day full of insightful talks, round tables and discussions and the theme of the day was: “Make Real-World Data the new hope for cancer patients”.

Some subjects and questions that were discussed today:
----------------------------------------
- Accès précoces et données de vie réelle : une chance française ?
- Comment la donnée de vie réelle peut-elle servir la recherche et les parcours de santé ?
- Bras de contrôle synthétiques : promesse ou mirage ?
- Plateforme de données en cancérologie : présent et perspectives.

L’Association "Filière Intelligence Artificielle & Cancers" a été créée le 3 août 2021. Elle est le fruit d’un partenariat public privé inédit et rassemble des représentants de l'Institut national du cancer, du Health Data Hub, de l'ALLIANCE POUR LA RECHERCHE ET L'INNOVATION DES INDUSTRIES DE SANTE, de France Biotech et de neuf des plus gros industriels de santé mondiaux en oncologie : Amgen, AstraZeneca, Bristol Myers Squibb, The Janssen Pharmaceutical Companies of Johnson & Johnson, MSD, Novartis, Pfizer, Pierre Fabre Group et Roche Diagnostics France.

Its ambition is to address, through all the data available in France, questions that bring value to patients and transform it into tangible innovations in the field of oncology.

23/01/2024

Rosetta Omics team had the privilege of participating in the AMI Oncomatch event organized by Medicen Paris Region and Canceropôle Île-de-France, held at Onepoint (Paris 16e) yesterday.

Our Founder and CEO, Dr. Wahid Awad Ph.D. MBA presented the vision behind Rosetta Omics and outlined our keen interest in fostering partnerships and collaborations.

Rosetta is actively seeking collaborations in the realms of multiomics, biopsies access, and artificial intelligence, aspiring to contribute to research consortiums at local, European, and global scales.

The Oncomatch call for expressions of interest serves as a catalyst, bringing together the entire oncology innovation ecosystem to nurture collaborative projects involving academic laboratories, clinics, startups, and industry partners. The goal is to streamline the formation of consortia and foster cross-disciplinary research projects capable of competing for partnership research project opportunities.

With more than 50 actors in oncology from Paris and allover France, in attendance, including Paris Saclay Cancer Cluster team, we engaged in fruitful discussions and exchanges on potential future projects.

It was truly gratifying to connect with both current and prospective partners, as well as many friends.

We look forward to continuing these discussions and collaborating to push the boundaries of innovation in cancer diagnosis and treatment.